Effects of Restrictive Fluid Management in Transient Tachypnea in Neonates

Document Type : Original Article

Authors

1 Clinical Research Development Unit of Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran

2 Student Research Committee, Babol University of Medical Sciences, Babol, Iran

3 Non-communicable Pediatric Disease Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran Clinical Research Development Unit of Rouhani Hospital, Babol University of Medical Sciences, Babol, Iran

Abstract

Background: The transient tachypnea is a common respiratory problem in the neonate. One of the significant issues in pathophysiology of this disorder is the delayed reabsorption of the fluid by the neonate’s lungs and the effusion of fluid in the lungs. The purpose of this study is to evaluate the effects of restrictive fluid management in transient tachypnea of the neonate.
Methods: The present study was conducted on the neonates with the gestational age ≥ 34 weeks suffering from transient tachypnea during the first 6 h after birth. The amounts of total fluid in experimental and control groups were 50, 65 mL/kg and 65, 80 mL /kg for term and preterm neonates, respectively. In each group, a daily amount of 20 mL/kg fluid was added until 150 and 170 mL/kg for term and preterm newborns.
Results: This study was carried out on 70 neonates, including 34 cases and 36 controls. The mean of hospitalization period in the experimental group was less than that of the control group. The mean period of respiratory support in the experimental group was less than that in the control group.
Conclusion: The results of the present study revealed that the restrictive fluid management in the neonates with transient tachypnea might decrease the hospitalization period and the respiratory support period. Furthermore, it is a safe and effective method in treating transient tachypnea in neonates.

Keywords


1. Martin RJ, Fanaroff AA, Walsh MC. Fanaroff and Martin's neonatal-perinatal medicine: diseases of the fetus and infant. New York: Elsevier Health Sciences; 2014.
 2. Gupta N, Chawla D. Fluid restriction in the management of transient tachypnea of the newborn. New York: The Cochrane Library; 2015.
3. Zahed PY, Zeynalzadeh M, Taheri T, Baleghi M. Correlation between the mode of delivery with the risk of neonatal respiratory morbidity. J Babol Univ Med Sci. 2008; 10(4):30-6.
4. Dani C, Reali MF, Bertini G, Wiechmann L, Spagnolo A, Tangucci M, et al. Risk factors for the development of respiratory distress syndrome and transient tachypnoea in newborn infants. Italian Group of Neonatal Pneumology. Eur Respir J. 1999; 14(1):155-9.
5. Stroustrup A, Trasande L, Holzman IR. Randomized controlled trial of restrictive fluid management in transient tachypnea of the newborn. J Pediatr. 2012; 160(1):38-43.
 6. Dehdashtian M, Aramesh MR, Melekian A, Aletayeb MH, Ghaemmaghami A. Restricted versus standard maintenance fluid volume in management of transient Tachypnea of newborn: a clinical trial. Iran J Pediatr. 2014; 24(5):575-80.
7. Kao B, Stewart de Ramirez SA, Belfort MB, Hansen A. Inhaled epinephrine for the treatment of transient tachypnea of the newborn. J Perinatol. 2008; 28(3):205-10.
 8. Armangil D, Yurdakök M, Korkmaz A, Yiğit Ş, Tekinalp G. Inhaled beta-2 agonist salbutamol for the treatment of transient tachypnea of the newborn. J Pediatr. 2011; 159(3):398-403.
9. Kim MJ, Yoo JH, Jung JA, Byun SY. The effects of inhaled albuterol in transient tachypnea of the newborn. Allergy Asthma Immunol Res. 2014; 6(2):126-30.
 10. Mohammadzadeh I, Akbarian-Rad Z, Heidari F, Zahedpasha Y, Haghshenas-Mojaveri M. The effect of inhaled salbutamol in transient of tachypnea of the newborn: a randomized clinical trial. Iran J Pediatr. 2017; 27(5):e9633.
 11. Karabayir N. Intravenous furosemide therapy in transient tachypnea of the newborn. Pediatr Int. 2010; 52(5):851.
12. Lewis VE, Whitelaw A. Furosemide for transient tachypnea of the newborn. Cochrane Database Syst Rev. 2002; 1:21.
 13. Yurdakok M, Ozek E. Transient tachypnea of the newborn: the treatment strategies. Curr Pharm Des. 2012; 18(21):3046-9.